financetom
Business
financetom
/
Business
/
Warren Buffett's Berkshire Hathaway exits China's BYD, filing shows
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Warren Buffett's Berkshire Hathaway exits China's BYD, filing shows
Sep 21, 2025 10:07 PM

BEIJING, Sept 22 (Reuters) - Warren Buffett's Berkshire

Hathaway ( BRK/A ) has fully exited Chinese automaker BYD

, a filing showed, ending a 17-year

investment that grew over 20-fold in value in that period.

The filing by Berkshire's energy subsidiary recorded the

value of its BYD investment as zero as of end-March, down from

$415 million at the end of 2024.

Buffett's company began investing in Shenzhen-based BYD in

2008, when it paid $230 million for about 225 million shares,

equivalent to a 10% stake at the time.

It began selling those shares in 2022 after BYD's share

price had risen more than twentyfold.

Berkshire did not immediately respond to a request for

comment on Monday. CNBC first reported Berkshire exiting its

stake on Sunday.

Li Yunfei, BYD's general manager of branding and public

relations, in a post on his official Weibo account thanked

Berkshire for its "investment, help and companionship over the

past 17 years."

He described the stake sale as a "normal" stock investment

trade. BYD did not immediately respond to a request for further

comment.

The biggest rival to Tesla saw quarterly profit

fall for the first time in three and a half years as its

expansion hit a speed bump amid a government campaign against

price wars.

BYD's domestic sales, which make up nearly 80% of its global

shipments, fell for a fourth straight month in August. It has

cut the annual sales target by as much as 16% to 4.6 million

vehicles, Reuters reported.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Wallbridge Mining Launches Phase Two Drilling at Martiniere Gold Project in Quebec
Wallbridge Mining Launches Phase Two Drilling at Martiniere Gold Project in Quebec
Jul 17, 2025
07:30 AM EDT, 07/17/2025 (MT Newswires) -- Wallbridge Mining ( WLBMF ) said Thursday that it commenced the second phase of drilling at the Martiniere gold project in Quebec. The phase two campaign will follow up on the positive results returned from phase one drilling of 7,225 meters that was completed in May. The company plans to complete a total...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
I-Mab to Acquire Bridge Health Biotech
I-Mab to Acquire Bridge Health Biotech
Jul 17, 2025
07:30 AM EDT, 07/17/2025 (MT Newswires) -- I-Mab ( IMAB ) said Thursday it has agreed to buy Bridge Health Biotech for an upfront payment of $1.8 million, plus $1.2 million in non-contingent payments through 2027. Bridge Health Biotech shareholders may also be entitled to future milestone payments of up to about $3.9 million, I-Mab ( IMAB ) said. The...
Rocket Pharmaceuticals' Drug Candidate for Heart Condition Receives FDA RMAT Designation
Rocket Pharmaceuticals' Drug Candidate for Heart Condition Receives FDA RMAT Designation
Jul 17, 2025
07:30 AM EDT, 07/17/2025 (MT Newswires) -- Rocket Pharmaceuticals ( RCKT ) said Thursday that the US Food and Drug Administration has granted regenerative medicine advanced therapy, or RMAT, designation to RP-A601, the company's experimental gene therapy for PKP2-arrhythmogenic cardiomyopathy, a heart condition. The designation was based on safety and efficacy data from a phase 1 trial. The designation offers...
Copyright 2023-2026 - www.financetom.com All Rights Reserved